ASCO Expands TAPUR Sites; Inks Collaborations to Investigate Precision Oncology Globally

Jun 04, 2017

|

CHICAGO (GenomeWeb) – The American Society of Clinical Oncology has expanded the Targeted Agent and Profiling Utilization Registry (TAPUR) study to around 100 sites in the US, and inked collaborations that will also bolster other countries' ability to explore precision oncology hypotheses.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

ASCO Expands TAPUR Sites; Inks Collaborations to Investigate Precision Oncology Globally

To read the full story....

Breaking News

European Regulators Recommend Approval of Roche Treatment for HER2-Positive Breast Cancer

Melanoma Patients See Magnified Benefit From Targeted Treatment Combo in Five-Year Outcomes Data

Lucence Diagnostics, MEDx Partner on Companion Diagnostic Cancer Tests in China

Colorectal Cancers Dial up Mutability in Response to Targeted Treatments

Merck, Promega Collaborate to Develop MSI CDx for Keytruda

Astellas' Xospata for FLT3-Mutated AML Garners European Commission Approval

Featured White Papers

Simultaneous Single-Cell DNA and Protein Sequencing in AML Samples

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of   FLT3  and  CEBPA

What's Popular?

FDA Clears NantHealth Tumor-Normal Whole-Exome Test

AMP Attendees Reflect on Uptake of Tumor Mutational Burden Amid Validation, Utility Questions

European Regulators Recommend Approval of Roche Treatment for HER2-Positive Breast Cancer

Melanoma Patients See Magnified Benefit From Targeted Treatment Combo in Five-Year Outcomes Data

Bristol-Myers, PathAI Show Artificial Intelligence Is on Par With Manual PD-L1 Scoring

Sponsorships